Get an email when this journal's indexing changes
Added to or removed from Scopus, Web of Science, ABDC, DOAJ, FT50, UT Dallas or ONOS. One confirmation click; unsubscribe anytime.
Drug Target Insights is Scopus-indexed (Q1, CiteScore 4.7), WoS ESCI, DOAJ. Published by AboutScience Srl.
Checked against the index lists dated .
ISSN 1177-3928Verify ISSN ↗
Publisher: AboutScience Srl
Cost to publish: Checking DOAJ for article charges…
| Subject area | Rank | Pctile | Q |
|---|---|---|---|
| Pharmacology, Toxicology and Pharmaceutics (all) | 17 / 79 | 79th | Q1 |
| Pharmacology (medical) | 110 / 278 | 60th | Q2 |
| Clinical Biochemistry | 59 / 124 | 52nd | Q2 |
Not listed in: ABDC, ABS / AJG, FT50, UT Dallas, ONOS (subscription), ONOS (APC covered)
Yes — actively indexed in Scopus, coverage 2011–present (also 2008–2009), best quartile Q1, CiteScore 4.7.
Drug Target Insights is Q1 in Pharmacology, Toxicology and Pharmaceutics (all) (rank 17 of 79), Q2 in Pharmacology (medical) (rank 110 of 278) and Q2 in Clinical Biochemistry (rank 59 of 124), by CiteScore 2025.
Drug Target Insights is indexed in the Emerging Sources Citation Index, so it may have a Journal Impact Factor in Clarivate's Journal Citation Reports. JCR is paid, so check it for the current value. The closest free measure is its Scopus CiteScore 4.7, which places it in quartile Q1 at the 79th percentile of its subject. Its SCImago Journal Rank (SJR, a free Scopus-based metric) is 0.692, quartile Q1, with an H-index of 20.
The publisher lists an article processing charge of about US$1,617 for open access (source: OpenAlex). Many journals also publish by the subscription route at no cost to the author, so confirm on the journal's own website.
Drug Target Insights is published by AboutScience Srl. Its ISSN is 1177-3928.
Yes — indexed in the Emerging Sources Citation Index.
Yes — it is an open-access journal, listed in DOAJ.
Drug Target Insights has an h-index of 27 and a 2-year mean of 3.71 citations per paper (OpenAlex). Its Scopus CiteScore is 4.7, quartile Q1. On 2-year citations it ranks #11 of 77 Scopus journals in Pharmacology, Toxicology and Pharmaceutics (all).
Drug Target Insights published 11 papers in 2025; its busiest recent year was 2023 with 16. 2026* is the year so far.
h-index, i10-index and 2-year mean citedness are open, licence-clear metrics from OpenAlex — not a proprietary impact factor. The subject rank counts only journals that OpenAlex has a figure for; it is not a Scopus or Clarivate ranking. Updated 2026-10-14.
In its latest 55 research articles (2021–2026), authors are most often from India (30.5%), Italy (14.1%) and Thailand (13.2%).
Countries are counted fractionally, so a paper by authors from two countries counts half to each.
Scopus status: Active. No retracted papers are recorded. The Problematic Paper Screener flags none of its papers. These are indicators to check, not findings against the journal.
Retractions from OpenAlex; flags from the Problematic Paper Screener (Cabanac, Labbé & Magazinov, CC BY), 2026-09-21 export. A flag marks a paper for a closer look; it is not a finding against the journal.
Index data is curated from public sources (Scopus, Web of Science, ABDC, FT50, UT Dallas, DOAJ). CiteScore and quartiles reflect the latest available Scopus release. Always verify a journal's current status on its official source before submitting.
Comments load as you scroll here.